Human T-Cell Lymphotropic Virus Types 1 and 2 (HTLV-1/-2) Antibody Screen with Confirmation, Spinal Fluid
Use
The test is used for the qualitative screening detection of human T-cell lymphotropic virus types 1 and 2 (HTLV-1/-2) specific antibodies with confirmation and differentiation between HTLV-1 and HTLV-2 infection. It provides confirmatory evidence of infection with HTLV-1 or HTLV-2 when screening is reactive, thereby aiding in the diagnosis of related disorders including adult T-cell leukemia or lymphoma and HTLV-1-associated myelopathy.
Special Instructions
Not provided.
Limitations
A negative test result does not exclude the possibility of exposure to HTLV-1 or HTLV-2, particularly in early infection when antibody levels may be undetectable. The performance characteristics have not been established for specimens with issues such as gross icterus, lipemia, hemolysis, or particulate matter. The test has been modified from the manufacturer's instructions and is not FDA cleared or approved.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Unknown protein
Protein
LOINC Codes
- 22361-0 - HTLV I+II Ab CSF Ql
- 22361-0 - HTLV I+II Ab CSF Ql
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.6 mL
Container
Sterile vial
Collection Instructions
Submit spinal fluid specimen from collection vial 1.
Causes for Rejection
Gross hemolysis, Gross lipemia, Precipitated specimens, Heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 30 days |